mp-1

MP-1 is a covalent inhibitor of fumarate hydratase (FH) that exhibits cytotoxicity dependent on FH. MP-1 engages a functional cysteine in the Zn-finger domain of the tRNA methyltransferase enzyme TRMT1.

BC-1485 is a small molecule inhibitor of FIEL1 (Fibrosis Inducing E3 Ligase 1) that inhibits the degradation of PIAS4 and ameliorates fibrosis in a mouse model.

Polybia-MP1 is an antimicrobial mastoparan peptide.

Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived inhibitory antibody against mouse GM-CSF that can specifically neutralize the GM-CSF factor. This antibody can be widely applied in research fields of cancer, infectious diseases, inflammatory diseases and immunology, including the research directions of cholangiocarcinoma, arthritis and others.

IMP-1710 is a selective UCH-L1 inhibitor with an IC50 value of 38 nM in a fluorescence polarization assay.IMP-1710 has antifibrotic activity. [1]

TMP-153 is a novel and potent ACAT inhibitor with an IC50 value of 5-10 nM for intestinal and hepatic ACAT in animals.TMP-153 has a hypocholesterolemic effect, inhibiting cholesterol uptake and lowering plasma cholesterol in rats and hamsters.

PAMP-12 (human, porcine) acetate (PAMP-12 (human, porcine) acetate (196305-05-2 free base)) , a major component of ir-PAMP, is processed from the AM precursor, as is PAMP-20, and may participate in cardiovascular control.

XMU-MP-1 is a reversible and selective MST1/2 kinase inhibitor, and its IC50 values for MST1 and MST2 are 71.1 nM and 38.1 nM, respectively.

MMP-11-IN-1 is a new class of phosphinate prodrugs. It is the glycosyl ester of RXP03 and can enhance blood-brain barrier (BBB) permeability.

IMP-1575 is a highly effective inhibitor of hedgehog acyltransferase (HHAT), with an IC50 of 0.75 μM when inhibiting purified HHAT. IMP-1575 has potential applications in cancer research.

BLIMP-1 ligand-1 (Compound 9) is a ligand for BLIMP-1 with a Kd value of 0.06 μM. It serves as a ligand for target proteins in the development of PROTAC BLIMP-1 degraders, such as PROTAC BLIMP-1 degrader-1, and is applicable in the study of multiple myeloma.

BLIMP-1 ligand-Linker Conjugate 1 is a conjugate consisting of BLIMP-1 ligand-1 and a linker. It has the capability to combine with CRBN ligand-881 to form PROTACBLIMP-1 degrader-1.

PROTACBLIMP-1 degrader-1 (Compound 49) is a BLIMP-1 PROTAC degrader. It facilitates the ubiquitination and degradation of BLIMP-1 and is applicable in research related to myeloproliferative neoplasms.

IMP-1002 is an inhibitor of Plasmodium N-myristoyltransferase (NMT). It suppresses myristoylation activity, thereby hindering parasite development. IMP-1002 is applicable in malaria-related research.

MMP-145 is used as a protease inhibitor.

MP-10 succinate is a potent and specific inhibitor of PDE10A.

MMP-9/MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of 0.9 nM for both enzymes. It is over 20 times more selective for MMP-9/MMP-13 than for other MMPs.

IMP-1700 is an inhibitor of bacterial DNA repair.1It potentiates the activity of the quinolone antibiotic ciprofloxacin against methicillin-resistantS. aureus(MRSA) with a combination index value of 0.7. IMP-1700 inhibits the ciprofloxacin-induced bacterial SOS response, a process that repairs DNA damage, in a reporter assay in a concentration-dependent manner. It is also active againstE. coli, as well as methicillin-resistant and -sensitive S. aureus, when used alone (EC50s = 0.5, 0.21, and 3.8 μM, respectively). 1.Lim, C.S.Q., Ha, K.P., Clarke, R.S., et al.Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureusBioorg. Med. Chem.27(20)114962(2019)

MP135 is a Novel μ−δ Opioid Receptor Heteromer-Selective Agonist. MP135 maintains untoward side effects such as respiratory depression and reward behavior; together, these results suggest that optimization of MP135 is necessary for the development of therapeutics that suppress the classical side effects associated with conventional clinical opioids.

MMP-1-IN-1 is a highly potent MMP-1 inhibitor with an IC 50 of 0.034 μM .

MMP-13 Substrate, a compound utilized in osteoarthritis (OA) research [1], functions as a substrate for MMP-13.

PAMP-12 (unmodified), an endogenous peptide and potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM), induces hypotension by inhibiting catecholamine release from sympathetic nerve endings and adrenal chromaffin cells [1].

PAMP-12 (unmodified) acetate is an endogenous peptide and potent agonist of the MRGPRX2 (MrgX2) receptor with an EC50 ranging from 20 to 50 nM. PAMP-12 (unmodified) mediates hypotensive effects by inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells, serving as a critical tool in the study of neuroimmune interactions and cardiovascular regulation.

PAMP-12 (unmodified) TFA, an endogenous peptide and potent MRGPRX2 (MrgX2) agonist (EC50=20-50 nM), induces hypotension by inhibiting catecholamine secretion from sympathetic nerve endings and adrenal chromaffin cells [1].